AstraZeneca

Companies AstraZeneca

News AstraZeneca

• Drug shown to reverse radioiodine resistance in some advanced thyroid cancers

  The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan-Kettering Cancer Center. Published in the issue of the New England Journal of more

• Public-private collaboration launches to tackle antibiotic research

  GlaxoSmithKline and AstraZeneca welcomed the launch of a pioneering approach to antibiotic research in Europe that will see pharmaceutical and biotechnology companies working alongside public partners to tackle the rising threat from antibiotic resistance and address some of the key barriers to the more

• BioFocus and Argenta Announce Drug Discovery Collaboration with AstraZeneca in Respiratory and Inflammatory Disease

  Galapagos’ service companies, BioFocus and Argenta, announced they have entered into a multi-year collaboration agreement with AstraZeneca to find new compounds against key targets of interest to AstraZeneca’s research programs in respiratory and inflammatory diseases. Under the terms of the collabo more

Publications AstraZeneca

• Seven days: 15–21 March 2013

  Seven days: 15–21 March 2013 Nature 495, 7441 (2013). http://www.nature.com/doifinder/10.1038/495286a The week in science: AstraZeneca cuts research posts as part of restructuring plans; Japan recovers methane from seabed hydrates; and Internet more

• Micronucleus induction in the bone marrow of rats by pharmacological mechanisms. II: long-acting beta-2 agonism

  AZD9708 is a new chemical entity with selective and long-acting β2-agonistic properties currently being evaluated by AstraZeneca for potential use in treatment of respiratory diseases by the inhaled route. As part of the toxicological characterisation of this compound, an increased incidence of mic more

• Second act [News Feature]

  Drug repurposing gets a boost as academic researchers join the search for novel uses of existing drugs.In February 2011, the British drug company AstraZeneca shelved its experimental drug zibotentan, intended for the treatment of nonmetastatic prostate cancer in men who do not respond to hormonal tr more

Market studies AstraZeneca

• Global Cancer Drug Market 2010-2014

  TechNavio’s analysts forecast the Global Cancer Drug market to grow at a CAGR of 12.6 percent over the period 2010–2014. One of the key factors contributing to this market growth is the increase in the prevalence of cancer worldwide. The Global Cancer Drug market in the Americas, and the EMEA and AP more

• Algeria Pharmaceuticals and Healthcare Report Q3 2012

  BMI View: With the push into emerging markets by pharmaceutical companies and the dangers of importing drugs into the Algerian market well documented, it makes sense that large multinational drugmakers would want to partner with local companies. High rates of foreign direct investment in the past ye more

• Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020”. The report is an essential source of information and analysis on the global ovarian cancer therapeutics market. The report provi more

Websites AstraZeneca